Controlled release of therapeutic agents: Slow delivery and cell encapsulation

World Journal of Urology

Volumn 18, Issue 1, 2000, Pages 80-83

  Machluf, Marcelle ^a   Orsola, Anna ^a   Atala, Anthony ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; GONADORELIN; TESTOSTERONE;

ANIMAL; ARTICLE; CELL; DELAYED RELEASE FORMULATION; HUMAN; RAT; TIME; URINARY TRACT DISEASE;

ANIMALS; CELLS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; GONADOTROPIN-RELEASING HORMONE; HUMANS; RATS; TESTOSTERONE; TIME FACTORS; UROLOGIC DISEASES;

EID: 0034137549     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003450050014     Document Type: Article

References (28)

1. Bagatell CJ, Bremner WJ (1996) Drug therapy: androgen in men - uses and abuses. N Engl J Med 334: 707
2. Bennett NJ (1998) A burn-like lesion caused by a testosterone transdermal system. Burns 24: 478-480
3. Bhasin S, Bremner WJ (1997) Clinical review of 85 emerging issues in androgen replacement therapy. J Clin Endocrinol Metab 82: 3-7
4. Canteril J, Dewis P, Large DM, et al (1984) Which testosterone therapy? Clin Endocrinol 21: 97-107
5. Chang TMS (1993) Bioencapsulation in biotechnology. Biomater Artif Cells Immobil Biotechnol 21: 291-293
6. Chang TMS (1998) Pharmaceutical applications of artificial cells including microencapsulation. Eur J Pharm Biopharm 45: 3-8
7. demons RD, Kappy MS, Stuart TE, et al (1993) Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty. Am J Dis Child 147: 653-656
8. Crook JM, Szumacher E, Malone S, et al (1999) Intermittent androgen suppression in the management of prostate cancer. Urology 53: 530-534
9. Franchi F, Luisi M, Kicovic PM, et al (1978) Long term study of oral testosterone undecanoate in hypogonadal males. Int J Androl 1: 270-278
10. Franchimont P, Kicovie PM, Mattei A, et al (1978) Effect of oral testosterone undecanoate in males. Clin Endocrinol 9: 313-320
11. Fujioka M, Shinohara Y, Baba S, et al (1986) Pharmacokinetic properties of testosterone propionate in normal men. J Clin Endocrinol Metab 63: 1361-1364
12. Gombotz WR, Pettit DK (1995) Biodegradable polymers for protein and peptide drug delivery. Bioconj Chem 6: 332-351
13. Gooren LJG (1994) A ten year safety study of the oral androgen testosterone undecanoate. Andrology 15: 212
14. Hogan DJ, Maibach HI (1990) Adverse dermatological reactions to transdermal drug delivery systems. J Am Acad Dermatol 22: 811-814
15. Kue PY, Saltzman WM (1996) Novel system for drug delivery of macromolecules. Crit Rev Eukaryot Gene Express 6: 59-73
16. Kwast TH, Tetu B, Candas B, et al (1999) Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prosthetic tumor volume: three versus six months of endocrine therapy. Urology 53: 523-529
17. Lim F, Sun AM (1980) Microencapsulated islets as bioartificial endocrine pancreas. Science 210: 908
18. Machluf M, Boorjian S, Caffaratti J, et al (1999) Therapeutic delivery of testosterone using microencapsulated Leydig cells (abstract). Proceedings, annual meeting of the American Urological Association. Dallas, May 2-9
19. McClellan KJ, Goa KL (1998) Transdermal testosterone. Adis New Drug Profile 55: 253-258
20. Savvas M, Studd JM, Norman S, Leather AT, et al (1992) Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post menopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynecol 99: 757-760
21. Snyder PJ (1984) Clinical use of androgens. Annu Rev Med 35: 207-217
22. Snyder PJ, Lawrence DA (1980) Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 51: 1335-1339
23. Sokol RZ, Palacios A, Campfield LA (1982) Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 37: 125-128
24. Sokol RZ, Palacios A, Campfield LA, et al (1982) Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril 37: 425-4130
25. Stuendle CS, Dudley RE (1990) Sublingual testosterone simulated episodic androgen release (abstract 426). Proceedings, 73rd Annual Meeting of the Endocrine Society, Las Vegas, 5-7 March 1990
26. Tai IT, Sun AM (1993) Microencapsulation of recombinant cells: a new delivery system for gene therapy. FASEB J 7: 1061
27. Wang T, Lacik I, Brissova M, et al (1997) An encapsulation system for the immunoisolation of pancreatic islets. Nat Biotechnol 15: 358-362
28. Wilson DE, Meikle AW, Boike SC, et al (1998) Bioequivalence assessment of a single 5 mg/day testosterone transdermal system versus two 2.5 mg/day systems in hypogonadal men. J Clin Pharmacol 38: 54-59